nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—HTR1F—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0492	0.0573	CbGpPWpGaD
Methylergometrine—HTR1E—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0464	0.054	CbGpPWpGaD
Methylergometrine—HTR1F—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0414	0.0481	CbGpPWpGaD
Methylergometrine—HTR1E—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.039	0.0454	CbGpPWpGaD
Methylergometrine—HTR2B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0289	0.0337	CbGpPWpGaD
Methylergometrine—DRD1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0273	0.0318	CbGpPWpGaD
Methylergometrine—HTR2B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0243	0.0283	CbGpPWpGaD
Methylergometrine—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0233	0.0272	CbGpPWpGaD
Methylergometrine—DRD1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0229	0.0267	CbGpPWpGaD
Methylergometrine—HTR1F—GPCRs, Other—CHRM3—nephrolithiasis	0.0219	0.0254	CbGpPWpGaD
Methylergometrine—HTR1F—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0209	0.0244	CbGpPWpGaD
Methylergometrine—HTR2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0203	0.0236	CbGpPWpGaD
Methylergometrine—HTR1E—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0198	0.023	CbGpPWpGaD
Methylergometrine—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0196	0.0228	CbGpPWpGaD
Methylergometrine—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0174	0.123	CcSEcCtD
Methylergometrine—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.017	0.0198	CbGpPWpGaD
Methylergometrine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0944	CcSEcCtD
Methylergometrine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0752	CcSEcCtD
Methylergometrine—HTR2B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00999	0.0116	CbGpPWpGaD
Methylergometrine—HTR1F—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00949	0.0111	CbGpPWpGaD
Methylergometrine—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.009	0.0105	CbGpPWpGaD
Methylergometrine—HTR1E—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00896	0.0104	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00894	0.0104	CbGpPWpGaD
Methylergometrine—DRD1—G alpha (s) signalling events—PTH—nephrolithiasis	0.00865	0.0101	CbGpPWpGaD
Methylergometrine—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00814	0.0577	CcSEcCtD
Methylergometrine—HTR1F—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00813	0.00947	CbGpPWpGaD
Methylergometrine—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00806	0.00939	CbGpPWpGaD
Methylergometrine—HTR1E—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00767	0.00893	CbGpPWpGaD
Methylergometrine—HTR2B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00722	0.00841	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00721	0.00839	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—RGS14—nephrolithiasis	0.00717	0.00835	CbGpPWpGaD
Methylergometrine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00711	0.0504	CcSEcCtD
Methylergometrine—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.007	0.00815	CbGpPWpGaD
Methylergometrine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00681	0.0483	CcSEcCtD
Methylergometrine—HTR1E—GPCR downstream signaling—RGS14—nephrolithiasis	0.00676	0.00787	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—RGS14—nephrolithiasis	0.00651	0.00758	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00646	0.00752	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00626	0.00729	CbGpPWpGaD
Methylergometrine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00624	0.0442	CcSEcCtD
Methylergometrine—HTR1F—GPCR ligand binding—CHRM3—nephrolithiasis	0.00619	0.00721	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—RGS14—nephrolithiasis	0.00614	0.00715	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR ligand binding—CHRM3—nephrolithiasis	0.00584	0.0068	CbGpPWpGaD
Methylergometrine—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00583	0.00679	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR ligand binding—PTH—nephrolithiasis	0.00566	0.0066	CbGpPWpGaD
Methylergometrine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.0056	0.0397	CcSEcCtD
Methylergometrine—HTR2B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00558	0.0065	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR ligand binding—PTH—nephrolithiasis	0.00534	0.00622	CbGpPWpGaD
Methylergometrine—DRD1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00527	0.00613	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00521	0.00607	CbGpPWpGaD
Methylergometrine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00515	0.0365	CcSEcCtD
Methylergometrine—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00506	0.00589	CbGpPWpGaD
Methylergometrine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00496	0.0351	CcSEcCtD
Methylergometrine—HTR1F—GPCR downstream signaling—DGKH—nephrolithiasis	0.00484	0.00564	CbGpPWpGaD
Methylergometrine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00478	0.00557	CbGpPWpGaD
Methylergometrine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00475	0.0337	CcSEcCtD
Methylergometrine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00464	0.0329	CcSEcCtD
Methylergometrine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.0046	0.0326	CcSEcCtD
Methylergometrine—HTR1E—GPCR downstream signaling—DGKH—nephrolithiasis	0.00457	0.00532	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00453	0.00527	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—ADCY10—nephrolithiasis	0.00452	0.00526	CbGpPWpGaD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00451	0.00525	CbGpPWpGaD
Methylergometrine—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0045	0.00525	CbGpPWpGaD
Methylergometrine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00444	0.0315	CcSEcCtD
Methylergometrine—HTR1F—Signaling by GPCR—DGKH—nephrolithiasis	0.0044	0.00512	CbGpPWpGaD
Methylergometrine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00427	0.0302	CcSEcCtD
Methylergometrine—HTR1E—Signaling Pathways—ADCY10—nephrolithiasis	0.00427	0.00497	CbGpPWpGaD
Methylergometrine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00424	0.03	CcSEcCtD
Methylergometrine—HTR2B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00422	0.00491	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—DGKH—nephrolithiasis	0.00415	0.00483	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00398	0.00463	CbGpPWpGaD
Methylergometrine—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00391	0.00455	CbGpPWpGaD
Methylergometrine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00389	0.0275	CcSEcCtD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00386	0.00449	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—RGS14—nephrolithiasis	0.00384	0.00448	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—RGS14—nephrolithiasis	0.00383	0.00446	CbGpPWpGaD
Methylergometrine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00376	0.0266	CcSEcCtD
Methylergometrine—HTR2B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00364	0.00424	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—RGS14—nephrolithiasis	0.00363	0.00422	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—RGS14—nephrolithiasis	0.00361	0.0042	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CHRM3—nephrolithiasis	0.0035	0.00408	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00344	0.004	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.0034	0.00396	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00335	0.0039	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—PTH—nephrolithiasis	0.00333	0.00388	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CHRM3—nephrolithiasis	0.0033	0.00384	CbGpPWpGaD
Methylergometrine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00325	0.00379	CbGpPWpGaD
Methylergometrine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00325	0.023	CcSEcCtD
Methylergometrine—HTR1F—GPCR downstream signaling—PTH—nephrolithiasis	0.0032	0.00373	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CHRM3—nephrolithiasis	0.00318	0.0037	CbGpPWpGaD
Methylergometrine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00314	0.0223	CcSEcCtD
Methylergometrine—DRD1—GPCR ligand binding—PTH—nephrolithiasis	0.00314	0.00366	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.00309	0.0036	CbGpPWpGaD
Methylergometrine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00302	0.0214	CcSEcCtD
Methylergometrine—HTR1E—GPCR downstream signaling—PTH—nephrolithiasis	0.00302	0.00352	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CHRM3—nephrolithiasis	0.003	0.00349	CbGpPWpGaD
Methylergometrine—Rash—Hydrochlorothiazide—nephrolithiasis	0.003	0.0212	CcSEcCtD
Methylergometrine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00299	0.0212	CcSEcCtD
Methylergometrine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00298	0.0211	CcSEcCtD
Methylergometrine—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00295	0.00344	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.00294	0.00342	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—PTH—nephrolithiasis	0.00291	0.00338	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00285	0.00332	CbGpPWpGaD
Methylergometrine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00282	0.02	CcSEcCtD
Methylergometrine—HTR1E—Signaling by GPCR—PTH—nephrolithiasis	0.00274	0.00319	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.00269	0.00313	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00269	0.00313	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00268	0.00312	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ADCY10—nephrolithiasis	0.00266	0.0031	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.0026	0.00302	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—DGKH—nephrolithiasis	0.0026	0.00302	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—DGKH—nephrolithiasis	0.00259	0.00301	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00255	0.00297	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ADCY10—nephrolithiasis	0.00251	0.00292	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00245	0.00285	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—DGKH—nephrolithiasis	0.00245	0.00285	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—DGKH—nephrolithiasis	0.00244	0.00284	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.00233	0.00272	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.0023	0.00267	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—RGS14—nephrolithiasis	0.00226	0.00263	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.00215	0.0025	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—RGS14—nephrolithiasis	0.00213	0.00248	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.00209	0.00243	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00206	0.0024	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00199	0.00232	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00194	0.00226	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—PTH—nephrolithiasis	0.00188	0.00219	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CHRM3—nephrolithiasis	0.00188	0.00219	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CHRM3—nephrolithiasis	0.00187	0.00218	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.00186	0.00217	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.00182	0.00212	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00181	0.00211	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PTH—nephrolithiasis	0.00178	0.00207	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CHRM3—nephrolithiasis	0.00177	0.00206	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00176	0.00205	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PTH—nephrolithiasis	0.00172	0.002	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PTH—nephrolithiasis	0.00171	0.00199	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00166	0.00193	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PTH—nephrolithiasis	0.00162	0.00189	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PTH—nephrolithiasis	0.00161	0.00188	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.00158	0.00184	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00153	0.00178	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—DGKH—nephrolithiasis	0.00153	0.00178	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.00152	0.00177	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.00151	0.00176	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00144	0.00168	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00144	0.00168	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—DGKH—nephrolithiasis	0.00144	0.00168	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.00138	0.00161	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.00132	0.00154	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.00131	0.00153	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.00123	0.00143	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00123	0.00143	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.0012	0.00139	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CHRM3—nephrolithiasis	0.0011	0.00129	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00107	0.00125	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.00107	0.00125	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CHRM3—nephrolithiasis	0.00104	0.00121	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTH—nephrolithiasis	0.00101	0.00118	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTH—nephrolithiasis	0.000953	0.00111	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000891	0.00104	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—SPP1—nephrolithiasis	0.000862	0.001	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000815	0.000949	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SPP1—nephrolithiasis	0.000813	0.000947	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000774	0.000901	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000734	0.000855	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTH—nephrolithiasis	0.000708	0.000824	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000655	0.000762	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000557	0.000648	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000557	0.000648	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SPP1—nephrolithiasis	0.000507	0.00059	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SPP1—nephrolithiasis	0.000478	0.000557	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	0.000409	0.000476	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.000397	0.000462	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	0.000359	0.000418	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	0.000355	0.000414	CbGpPWpGaD
